Matrix-M™ adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in mice
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1559-0755
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Matrix-M™ adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in mice ; volume:66 ; number:2 ; day:28 ; month:3 ; year:2018 ; pages:224-233 ; date:4.2018
Immunologic research ; 66, Heft 2 (28.3.2018), 224-233, 4.2018
- Creator
-
Magnusson, Sofia E.
- Contributor
-
Altenburg, Arwen F.
Bengtsson, Karin Lövgren
Bosman, Fons
Vries, Rory D. de
Rimmelzwaan, Guus F.
Stertman, Linda
SpringerLink (Online service)
- DOI
-
10.1007/s12026-018-8991-x
- URN
-
urn:nbn:de:101:1-2018061710090352695227
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:35 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Magnusson, Sofia E.
- Altenburg, Arwen F.
- Bengtsson, Karin Lövgren
- Bosman, Fons
- Vries, Rory D. de
- Rimmelzwaan, Guus F.
- Stertman, Linda
- SpringerLink (Online service)
Other Objects (12)
Phase 2a safety and immunogenicity testing of DNA and recombinant modified vaccinia ankara virus vaccines expressing virus-like particles
Personalized neoantigen-pulsed dendritic cell vaccines show superior immunogenicity to neoantigen-adjuvant vaccines in mouse tumor models
Synthetic modified vaccinia Ankara vaccines confer cross-reactive and protective immunity against mpox virus
Improving the cellular immunogenicity of recombinant Modified Vaccinia virus Ankara using green fluorescent protein as model system
Heat-inactivated modified vaccinia virus Ankara boosts Th1 cellular and humoral immunity as a vaccine adjuvant
Recombinant modified Vaccinia Virus Ankara (MVA) vaccines efficiently protect cockatiels against parrot bornavirus infection and proventricular dilatation disease
Effects of pre-existing orthopoxvirus-specific immunity on the performance of Modified Vaccinia virus Ankara-based influenza vaccines
Immunogenicity and Protection Against Influenza H7N3 in Mice by Modified Vaccinia Virus Ankara Vectors Expressing Influenza Virus Hemagglutinin or Neuraminidase
Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics
Next-generation mpox vaccines: efficacy of mRNA-1769 compared to modified vaccinia virus Ankara in non-human primates
Immunogenicity of poxvirus-based vaccines against Nipah virus
Correction: Next-generation mpox vaccines: efficacy of mRNA-1769 compared to modified vaccinia virus Ankara in non-human primates
Phase 2a safety and immunogenicity testing of DNA and recombinant modified vaccinia ankara virus vaccines expressing virus-like particles
Personalized neoantigen-pulsed dendritic cell vaccines show superior immunogenicity to neoantigen-adjuvant vaccines in mouse tumor models
Synthetic modified vaccinia Ankara vaccines confer cross-reactive and protective immunity against mpox virus
Improving the cellular immunogenicity of recombinant Modified Vaccinia virus Ankara using green fluorescent protein as model system
Heat-inactivated modified vaccinia virus Ankara boosts Th1 cellular and humoral immunity as a vaccine adjuvant
Recombinant modified Vaccinia Virus Ankara (MVA) vaccines efficiently protect cockatiels against parrot bornavirus infection and proventricular dilatation disease
Effects of pre-existing orthopoxvirus-specific immunity on the performance of Modified Vaccinia virus Ankara-based influenza vaccines
Immunogenicity and Protection Against Influenza H7N3 in Mice by Modified Vaccinia Virus Ankara Vectors Expressing Influenza Virus Hemagglutinin or Neuraminidase
Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics
Next-generation mpox vaccines: efficacy of mRNA-1769 compared to modified vaccinia virus Ankara in non-human primates
Immunogenicity of poxvirus-based vaccines against Nipah virus
Correction: Next-generation mpox vaccines: efficacy of mRNA-1769 compared to modified vaccinia virus Ankara in non-human primates
Phase 2a safety and immunogenicity testing of DNA and recombinant modified vaccinia ankara virus vaccines expressing virus-like particles
Personalized neoantigen-pulsed dendritic cell vaccines show superior immunogenicity to neoantigen-adjuvant vaccines in mouse tumor models
Synthetic modified vaccinia Ankara vaccines confer cross-reactive and protective immunity against mpox virus
Improving the cellular immunogenicity of recombinant Modified Vaccinia virus Ankara using green fluorescent protein as model system
Heat-inactivated modified vaccinia virus Ankara boosts Th1 cellular and humoral immunity as a vaccine adjuvant
Recombinant modified Vaccinia Virus Ankara (MVA) vaccines efficiently protect cockatiels against parrot bornavirus infection and proventricular dilatation disease
Effects of pre-existing orthopoxvirus-specific immunity on the performance of Modified Vaccinia virus Ankara-based influenza vaccines
Immunogenicity and Protection Against Influenza H7N3 in Mice by Modified Vaccinia Virus Ankara Vectors Expressing Influenza Virus Hemagglutinin or Neuraminidase
Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics
Next-generation mpox vaccines: efficacy of mRNA-1769 compared to modified vaccinia virus Ankara in non-human primates
Immunogenicity of poxvirus-based vaccines against Nipah virus